Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma
ASH 2019 – Multiple Myeloma
LCAR-B38M CAR-T Therapy Yields High Complete Response Rate and Survival Time
ASH 2019 – Multiple Myeloma
Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative.
Read More ›
GRIFFIN Study: Daratumumab Deepens Responses Over Time
ASH 2019 – Multiple Myeloma
Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses.
Read More ›
Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma
ASH 2019 – Multiple Myeloma
Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes.
Read More ›
Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial
ASH 2019 – Multiple Myeloma
For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed.
Read More ›
Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma
ASH 2019 – Multiple Myeloma
After induction with daratumumab and CyBorD, maintenance daratumumab improves depth of response and survival in newly diagnosed and relapsed multiple myeloma.
Read More ›
Benefit Shown for Daratumumab plus Carfilzomib + Dexamethasone
ASH 2019 – Multiple Myeloma
Presented as a late-breaking abstract, CANDOR met its primary end point, showing that daratumumab/carfilzomib/dexamethasone significantly prolonged progression-free survival.
Read More ›
Study Moves CAR-T Therapy Forward in Myeloma
ASH 2019 – Multiple Myeloma
Responses were achieved by more than 90% of patients receiving JNJ-4528, and all patients tested for minimal residual disease (MRD) status were MRD-negative.
Read More ›
Videos
What is Minimal Residual Disease (MRD) Negativity?
By
Leslie Lauersdorf, ARNP
ASH 2019 – Multiple Myeloma
Leslie Lauersdorf breaks down what it means to be MRD negative and how she explains MRD negativity to her patients.
Read More ›
In Routine Practice, Ixazomib Regimen Mirrors Efficacy of Clinical Trial
ASH 2019 – Multiple Myeloma
In an analysis of more than 10,000 relapsed/refractory patients treated in routine clinical practice with ixazomib/lenalidomide/dexamethasone, outcomes were as good as those reported in clinical trials.
Read More ›
Videos
Multiple Myeloma as a Chronic Disease
By
Leslie Lauersdorf, ARNP
ASH 2019 – Multiple Myeloma
As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients.
Read More ›
Page 1 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us